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Abstract
Background: Glucocorticoid is widely used as an
anti-inflammatory drug in various diseases however
excess of it often causes cardiovascular
complications. The present study was undertaken to
understand the molecular mechanism of
glucocorticoid-induced cardiac dysfunction. Methods:
Rats were treated daily with synthetic glucocorticoid,
dexamethasone with or without mifepristone or
losartan up to 15 days. Hemodynamic parameters
were measured by PV-loop method using Millar’s
instrument. Cardiac remodelling, fibrosis and oxidative
stress were monitored after 15 days. Results: The
systolic blood pressure was increased whereas the
heart beat and cardiac output (n=6) were decreased
by dexamethasone. Dexamethasone caused increase
in the heart weight to body weight ratio (P<0.001,
n=20), increased level of mRNA of atrial natriuretic
peptide and an increased deposition of collagens in
the extracellular matrix of the left ventricle which were
inhibited by both mifepristone and losartan. The rate
of oxygen consumption was decreased in association
with increased levels of hypoxia inducible factor 1?,
lipid peroxidation (P<0.01, n=3) and superoxide
dismutase activity (P<0.01, n=3) in dexamethasone
treated rat heart. All these changes were reversed
by mifepristone and losartan. Conclusions: The
excess of glucocorticoid induces cardiac remodelling
and pathophysiolgical changes of the myocardium via
angiotensin II signalling pathway.
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Introduction
Glucocorticoid (GC) is commonly used as an anti-
inflammatory drug but GC therapy is often limited by
several adverse reactions because excess of it exhibits a
variety of symptoms including complications of
cardiovascular system [1-7]. Specifically, it was
demonstrated that excess of GC induced hypertension
and atherosclerosis [5]. Furthermore, a synthetic GC,
2dexamethasone (DEX) was shown to induce hypertension
via the mediation of peroxisome proliferator activator
receptor ? (PPAR-?) which is known to be critically
involved during cardiac hypertrophy and remodelling [2].
However, it is not known whether excess of GC causes
myocardial remodelling in heart similar to other
hypertrophic stimuli.
Remodelling of the myocardium is one of the most
detrimental effects of chronic hypertension [8-10]. Due
to an increased work load during chronic hypertension
myocyte hypertrophy occurs resulting in ventricular
enlargement which is initially beneficial to the
cardiovascular system [11, 12]. However, in the long run,
such compensatory enlargement of the left ventricle
becomes maladaptive leading to the contractile
dysfunction and heart failure [13]. Remodelling of the
left ventricle during hypertrophic growth is associated with
an enhanced collagen synthesis which results into
interstitial fibrosis causing myocardial stiffness and
contractile abnormality [14]. Because of increased fibrosis
the adjoining myocytes may pose insufficient supply of
oxygen which could result into myocardial hypoxia [15]
and oxidative stress [16-18].
Usually, hypertension-induced LV remodelling is
mediated via angiotensin II (Ang II). Inhibition of Ang II
type 1 (AT1) receptor with angiotensin receptor blockers
regresses LV remodelling and improves cardiac function
in the diseased hearts suggesting that Ang II has a direct
role in the development of cardiac hypertrophy, fibrosis
and dysfunction [19, 20]. Both circulating as well as locally
produced Ang II binds to AT1 receptor on cardiomyocytes
and stimulates hypertrophic growth of the cells [21-23].
Furthermore, Ang II was shown to mediate the oxidative
stress-induced transition to LV failure in rat [20].
Therefore, Ang II has a pivotal role in the progression of
cardiac dysfunction and heart failure in a variety of
pathological situations [24].
Although GC excess has been known to cause
severe side effects in heart, the mechanisms involved in
GC-induced cardiac malfunction were not investigated.
Therefore, we examined whether LV remodelling and
contractile abnormality are responsible for cardiovascular
complications due to GC excess. Here we have
demonstrated that treatment of rat with synthetic
glucocorticoid, dexamethasone (DEX) resulted into
extensive remodelling of the heart accompanied by
fibrosis, hypoxia, and oxidative stress and decreased LV
functions via Ang II pathway. These informations are
entirely new in light of the molecular mechanism of
cardiovascular malfunction due to excess of GC.
Materials and Methods
Animal
Male Sprague-Dawley (SD) rats were received from the
Institute’s animal facility. The animals were handled as per the
guidelines of Institutional animal ethics committee in accordance
with the committee for the purpose of control and supervision
of experiment on animals, Ministry of Social Justice, Government
of India.
Administration of rat with drugs
Male SD rats (220 g BW) were treated with DEX (35 µg/
100g BW, orally once daily) for 15 days. To examine the effect
of excess of GC, relatively high dose of DEX was used based
on the reports that DEX induces cardiovascular disorders [3-
5]. To examine the involvement of GR and Ang II in mediating
the cardiovascular complications, the GR antagonist,
mifepristone (MIF, 2 mg/100 g/BW, orally once daily) and the
AT 1 receptor blocker, losartan (2 mg/100g/BW, orally once
daily) were co-administered [3, 25] separately with DEX for
similar periods. The rationale for terminating the studies at 15
days was that daily administration of DEX with the above dose
beyond 15 days caused mortality of rats that increased gradually
with the duration of the treatment [26].
Hemodynamic study
The rats were anesthetized with sodium pentobarbital (50
mg/kg BW) and heparine (500 units/kg BW). The right internal
carotid artery was identified and ligated cranially. A miniaturized
conductance catheter (SPR-838 Millar instruments, Houston,
TX) was inserted into the carotid artery and then advanced
into the left ventricle until stable PV loops were obtained [27].
Data were then acquired under steady state conditions. Using
the pressure conductance data a range of functional parameters
were then calculated (Millar analysis software PVAN 3.4). Each
experiment was repeated with six animals.
Assessment of cardiac hypertrophy
The rats were weighed and sacrificed by cervical
dislocation, and hearts were surgically removed and immersed
in ice-cold 0.9% NaCl. The ventricles were collected, weighed
and stored in -80°C for future use. The degree of hypertrophy
was calculated in terms of heart (ventricular) weight/body
weight (HW/BW) ratio.
Real time quantitative RT-PCR
Levels of atrial natriuretic peptide (ANP), brain natriuretic
peptide (BNP) and AT 1 receptor mRNAs were measured by
real time quantitative RT-PCR using the Dynamo™ SYBR® Green
qPCR Kit (Finnzymes, Finland) and the iCycler real time detection
system and software (Bio-Rad Laboratories, Hercules, CA,
USA). For RT-PCR reactions (20 µl), equal amount (500 ng) of
total RNA was used. The list of PCR primers were presented in
Tab. 1. The level of expression was calculated as fold change
compared to control using the Ct value after normalizing with
the GAPDH as described earlier [26]. Experiment was repeated
with samples from 6 different rats.
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3Histological studies
After 15 days of treatment, hearts were collected and
immediately fixed in 10% formalin and embedded in paraffin
following routine procedure as described earlier [26]. Left
ventricular sections (5 µM thick) were prepared and stained
with hematoxylin-eosin (Sigma Chemical Co, Louis, MO, USA).
The stained tissue sections were examined under Olympus
BX51 (Olympus Corporation, Tokyo, Japan) microscope and
images were captured with a digital camera attached to it. To
measure the myocyte cross-sectional area, each HE stained LV
section was observed under 400 x magnification using the same
microscope and images were captured. Peripheral margin of 20-
30 myocytes was manually traced and cross sectional area was
measured [26, 28-29] using Olympus Micro Image (version 4.5)
software.
Quantification of fibrosis by Confocal Microscopy
Left ventricular sections (5 ?M thick) were stained with
Sirius red (Direct Red 80; Sigma Chemical Co, Louis, MO, USA)
and imaged with laser scanning confocal system (Leica TCS,
SP2, Germany) and the stacked images through multiple slices
were captured. The digitized images were then analysed using
image analysis system (Image J, NIH Software, Bethesda, MI)
and the total collagen area fraction of each image was measured
and expressed as the % collagen volume as described earlier
[26, 30].
Oxygen consumption study
Hearts were perfused with ice cold 0.9% saline. About
100 mg of tissue was obtained from the left ventricle. Then
tissues were minced with sharp scissors into approximately
0.3-0.4 mm in diameter. Mitochondrial respiration was measured
by monitoring oxygen (O
2
) uptake as previously described [31]
using an YSI 5300A biological oxygen monitor. The amount of
O
2
consumption was calculated for each sample from the plotted
graph.
Western Blot Analysis
The whole homogenate from left ventricular tissues was
prepared as described earlier [26, 32]. Briefly, the left ventricle
was homogenized in a buffer containing 50 mM Tris-HCl (pH
7.4), 150 mM NaCl, 1 mM PMSF, 1mM sodium orthovanadate,
1 µg/ml each of pepstatin A, leupeptin, and aprotinin. Equal
amount of proteins (60 µg) was resolved in 10% SDS-PAGE for
immunoblotting with antibodies for hypoxia inducible factor
1? (HIF-1?) and heat shock protein 70 (HSP-70) and actin (Santa
Cruz Biotechnology Inc., CA).
Determination of lipid peroxidation in cardiac tissue
Left ventricular tissue (200 mg) was homogenized in ice-
cold 0.9 saline (pH 7.0) with a Potter-Elvehjem glass homogenizer
for 30 sec. The lipid peroxides in the homogenate was
determined as thiobarbituric acid reactive substances (TBARS)
by previously described method [33, 34]. Briefly, the
homogenate was mixed with TBA-TCA (Thiobarbituric acid-
Trichloro acetic acid) reagent with thorough shaking and boiled
for 15 min in a boiling water bath. The samples were then cooled
to room temperature. The absorbance of the pink chromogen
present in the clear supernatant obtained after centrifugation
was measured at 532 nm using a UV-VIS spectrophotometer.
The amount of lipid peroxidation was calculated in terms of the
level of TBARS.
Lactate Assay
Blood was collected directly from the heart of anesthetized
animal and lactate concentration in the serum was measured
using commercially available Enzy Chrom Lactate Assay Kit
(Bioassay Systems, Hayward, CA, USA).
Measurement of superoxide dismutase activity
The activity of Cu,Zn-superoxide dismutase (Cu,Zn-SOD)
was determined in rat heart following xanthine oxidase-
cytochrome C method [35] with some modifications. Briefly,
500 mg ventricular tissue was homogenized in a buffer
containing 0.2 mM EDTA, 0.25 M sucrose, 10 mM Tris-HCl, pH
7.8) in the presence of protease inhibitor cocktail following
centrifugation at 1000 x g for 10 minutes to remove nuclear
debris. The supernatant was collected and spun at 12000 x g
for 10 minutes. The supernatant was collected and used for
Cu,Zn-SOD assay. The SOD assay was performed
spectrophotometrically at 550 nm with a xanthine/xanthine
oxidase, a superoxide generating system, in the presence of
cytochrome C. The SOD activity was expressed as units/mg
protein. The experiment was repeated 3 times with different
individual rats.
Catalase Assay
Frozen myocardium (0.2 gm) was homogenized in 0.5 ml
of ice-cold phosphate buffer (0.05 M, pH 7.0). The homogenate
was centrifuged at 12000 x g for 12 min. The supernatant was
collected and 0.01 ml of absolute ethanol was added and
incubated at 4°C for 30 min prior to the addition of 10% Triton
X-100 to a final concentration of 1%. The addition of ethanol is
thought to prevent peroxisomal H
2
O
2
 generation and thus
protect catalase activity during extraction. The samples thus
Table 1. List of primers.
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4obtained, were then used to determine catalase activity as
described earlier [36].
Statistical Analysis
The data are presented as the mean ? S.E.M. Most of the
experiments were conducted independently at least with
3 animals. For real time PCR analysis, 6 rats were used in each
group. Hypertrophy of heart was calculated based on 20 rats in
each set of experiment. Data were evaluated by one-way
analysis of variance using the software Microcal Origin 6.0
(Microcal Software Inc, MA, USA). A level of P<0.05 was
considered the threshold for statistical significance between
the control and various experimental groups.
Results
Dexamethasone causes cardiac dysfunction via
angiotensin II pathway
As shown in Tab. 2, the systolic blood pressure was
significantly (P>0.01, n=6) increased in DEX treated rat
(Pmax, 147.93 ± 1.54 mm Hg) compared to that of control
(Pmax, 108.35 ± 4.6 mm Hg). The heart beat and cardiac
output (CO) were significantly reduced in DEX treated
rat. The parameter of diastolic function (dP/dt min) was
significantly reduced by DEX compared to control.
Both MIF and losartan significantly restored DEX-induced
alteration of the hemodynamic parameters.
Involvement of Ang II in glucocorticoid-induced
myocardial remodelling
Rats were administered with DEX for different
duration up to 15 days. There was a gross enlargement
Table 2. Hemodynamic parameters of heart function. *P< 0.01 vs control, n=6.
Table 3. Dexamethasone-induced cardiac hypertrophy is inhibited by mifepristone
and losartan. *P< 0.001 vs control, n=20.
of the myocardium after 15 days of treatment with
DEX (Fig. 1A). Co-administration with either GR
antagonist, MIF or AT 1 receptor blocker, losartan, clearly
inhibited DEX-induced enlargement of the myocardium
(Fig. 1A). The absolute weight of heart (combined left
and right ventricle) was 24% greater than control  (Tab.
3). The HW/BW ratio was gradually increased with the
duration of treatment (Fig. 1B) which was significantly
higher after 15 days of treatment (P<0.001, n=20).
Cardiac hypertrophy did not occur when MIF or losartan
separately co-administered with DEX.
To further confirm the involvement of Ang II for the
induction of cardiac hypertrophy, the expression of
hypertrophic marker, ANP and BNP was also examined.
As shown in Fig. 1C, the expression of ANP mRNA was
increased with the duration of DEX treatments attaining
a 4-fold induction (4.22 ± 0.11, P<0.01, n=6) over control
after 15 days. Similarly, there was a time dependent
induction of BNP expression (Fig. 1D) which was about
6 fold higher after 15 days of treatment (P<0.01, n=6).
These increases were prevented by treatment with
MIF or losartan (Figs. 1C, 1D). Treatment of rat
separately either with MIF or losartan alone did not have
any effect on HW/BW ratio (data not shown). Therefore,
the effect of MIF or losartan alone on the other parameters
was not shown in the subsequent experiments.
Histology of the left ventricle
The left ventricular sections showed cellular
hypertrophy in DEX treated rat (Fig. 2A). The cross
sectional area of the myocytes was significantly
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5Fig. 1. Involvement of angiotensin pathway in dexamethasone-
induced cardiac hypertrophy. Representative image showing
enlarged ventricular portion after 15 days of treatment with
either vehicle (CON), dexamethasone (DEX) or dexamethasone
with mifepristone (DEX+MIF) or losartan (DEX+LOS). B. The
degree of hypertrophy (HW/BW) of rats treated with DEX for
5 days (d5), 10 days (d10) and 15 days (d15) are shown along
with regression when co-treated with either mifepristone (MIF)
or losartan (LOS). This data represents mean ? SEM for 20 rats
in each group. *P<0.001 vs control (n=20). Real time RT-PCR
showing ANP (C) and BNP (D) gene expressions as fold change
over control after normalizing with GAPDH mRNA expression
in left ventricle of similar experimental group. Data represents
mean ? SEM from 6 animals, in duplicates. *P<0.01 vs control
(n=6).
Fig. 2. Ventricular remodelling and
fibrosis. Representative images (400 X
magnification) of hematoxyline-eosine
stained cross sections (A) through left
ventricles of rats treated with vehicle
(CON) or dexamethasone (DEX) or
dexamethasone with mifepristone
(DEX+MIF) or dexamethasone with
losartan (DEX+LOS) for 15 days. (B)
Images (600 X magnification) shown are
the left ventricular tissue sections
stained with Sirius red. Red color
stretches are collagen depositions. (C)
The similar images were captured by
laser scanning confocal microscope for
quantification of fibrosis. Arrow heads
indicate collagen fibers. (D) Myocyte
cross-sectional area calculated from the
hematoxyline and eosin-stained sections
as shown in (A). Each bar represents
myocyte cross-sectional areas in mean ±
SEM of square pixels of 3 images from 3
individual rats (* P<0.01 vs control, n=3).
(E) Histogram showing % collagen
volume in the left ventricular tissues.
Data indicate mean ± SEM % collagen
volume obtained from 3 images from each
of 3 different rats.
increased in DEX treated rat heart compared to
control (Fig. 2D). When MIF or LOS were
co-administered separately with DEX, the cross sectional
area of the myocytes was similar to that of control
tissue (Fig. 2D). As revealed by picrosirius red staining,
there was an increased deposition of collagens in the
ventricular sections in DEX treated rat compared to those
of control (Figs. 2B, 2C).  The volume of total collagens
was also increased significantly (P<0.01, n=3) in DEX
treated rat heart which was decreased to the normal
level in the presence of MIF or losartan (Fig. 2E)
indicating that the development of cardiac fibrosis in
DEX treated rat was mediated both via GR and
AT 1 receptor.
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6Dexamethasone induces the expression of AT 1
receptor genes
Since inhibition of Ang II by losartan inhibited DEX-
induced cardiac hypertrophy and remodeling, the mRNA
level of AT 1 receptor in the LV was measured by real
time quantitative RT-PCR using gene specific primers.
The level of AT1 receptor (Fig. 3) mRNA were increased
significantly (P<0.01, n=6) by DEX which was blocked
when co-administered with MIF. In contrast, co-treatment
with losartan did not inhibit DEX-induced expression of
AT1 receptor.
Effect of GC excess on cellular respiration in
heart
Oxygen consumption is one of the important
parameters of mitochondrial respiration and heart function.
Hence, oxygen consumption in cardiac tissue was
measured after 15 days with DEX in the absence or
presence of either MIF or losartan. As shown in Fig. 4,
the oxygen consumption was significantly (P<0.01, n=3)
decreased in DEX treated rat heart which was restored
to the level of control tissue when co-administered either
with MIF or losartan. The result suggested that DEX
considerably affect mitochondrial respiration in heart via
the Ang II mediated signalling pathway.
Induction of hypoxia-inducible factor by
dexamethasone
To examine whether cellular hypoxia induces the
expression of hypoxia-inducible factor, LV homogenates
were subjected to western blotting analysis with anti-HIF-
1? antibody. As shown in Fig. 5, treatment of rat with
DEX enhanced the level of HIF 1? in cardiac tissue which
was inhibited by MIF as well as losartan.
Dexamethasone induces oxidative stress in heart
Since oxidative stress is known to affect
cardiovascular functions directly in a variety of
pathological conditions and glucocorticoid directly
influences mitochondrial function, we examined whether
oxidative stress is generated in ventricular tissue due to
the treatment with DEX. As shown in Fig. 6, the level of
lipid peroxidation was significantly (P<0.01) increased by
DEX which was inhibited by MIF and losartan.
To examine the involvement of mitochondria and
oxidative stress, we examined the level of HSP-70
expression in LV homogenates and lactate level in serum.
As shown in Fig. 7A, the expression of HSP-70 was
increased by DEX. The level of lactate was also
increased significantly (P<0.01, n=3) in DEX treated rat
Fig. 3. Effect of DEX on AT1 receptor mRNA levels in left
ventricle. Real time quantitative RT PCR analysis showing the
expression of AT1 receptor gene in the left ventricular tissue of
rats treated with vehicle (CON) or dexamethasone (DEX) or
DEX in combination with either mifepristone (DEX+MIF) or
losartan (DEX+LOS) for 15 days. Data represents mean ? SEM
from 6 animals, in duplicates. *P<0.01 vs control (n=6).
Fig. 4. Oxygen consumption. Rate of respiration was measured
using ventricular tissues of rat treated either with vehicle (CON)
or dexamethasone (DEX) or dexamethasone with mifepristone
(DEX+MIF) or dexamethasone with losartan (DEX+LOS) for
15 days. Ventricular tissue was minced to very small pieces and
the rate of oxygen uptake was measured as described in
Materials and Methods. Each bar represents mean ? SEM of 3
separate observations (n=3). *Significantly different at P <0.01
vs control.
compared to control. DEX-induced HSP -70 expression
was reversed partially whereas lactate level was restored
significantly by MIF and LOS (Figs. 7A, 7B).
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7Fig. 5. Monitoring marker for hypoxia. Expression of HIF-1?
in the LV homogenates of rat treated with vehicle (CON) or
dexamethasone treated alone (DEX) or in combination with
either mifepristone (DEX+MIF) or losartan (DEX+LOS). The
equal amount of protein (70 µg) was loaded onto the
polyacrylamide gel and the immunoblotting analysis was
conducted with anti-HIF-1? antibody. Histogram showing mean
pixel intensities (arbitrary units) of 3 immunoblots performed
with different individual rats (n=3). *Significantly different
compared to control at P<0.01.
Fig. 6. Lipid peroxidation in rat heart tissues. LV homogenates
from rats treated with vehicle (CON) or dexaemthasone (DEX)
alone or dexamethasone in combination with either mifepristone
(DEX+MIF) or losartan (DEX+LOS) were subjected to
estimation of lipid peroxidation. Lipid peroxidation is expressed
as pmoles TBARS/mg protein. Data represents mean ? SEM of
3 animals (n=3) and *indicates significantly different compared
to control at P<0.01.
To examine the status of endogenous antioxidants,
the activities of SOD and catalase were examined in LV
homogenates. The activity of SOD was significantly
(P<0.01, n=3) increased whereas the catalase activity
was significantly (P<0.01, n=3) decreased by DEX
compared to control (Figs. 8A, 8B). These changes were
significantly prevented by MIF and losartan.
Fig. 7. DEX induces the expression of HSP-70 in LV and lactate
in serum. Immunoblotting analysis to examine the expression
of heat shock protein (HSP-70) in the ventricular tissue
homogenate (50 µg) of rat treated with vehicle (CON) or
dexamethasone alone (DEX) or in combination with either
mifepristone (DEX+MIF) or losartan (DEX+LOS). B. The serum
collected from similar experimental groups was subjected to
lactate estimation as described in the “Materials and Methods”.
Each bar represents mean ? SEM of 3 separate animals in each
experimental group. *indicates significantly different compared
to control at P<0.01.
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8Discussion
The present study demonstrates one possible
mechanism of cardiac toxicity due to an excess of GC
administration. The molecular basis of GC-induced
cardiac malfunction could be attributed to extensive
myocardial remodeling, hypoxia and oxidative stress.
Importantly, all these effects are mediated via the AT1
receptor suggesting that Ang II pathway is critically
involved in GC-induced pathophysiological changes of
the myocardium.
Application of glucocorticoid for a prolonged period
may cause gross enlargement of the ventricle as shown
in the present study (Figs. 1A, 1B). Consistent with our
earlier report [26], GC-induced enlargement of the
myocardium is accompanied by increased level of ANP
and BNP mRNAs and massive remodelling of the
extracellular matrix (ECM) as shown in Figs. 1 and 2.
Since GC primarily acts via GR which belongs to nuclear
hormone receptor family [37], GR antagonist MIF,
significantly blocks hypertrophy and expression of ANP
and BNP (Fig. 1). It is likely that activation of the Ang II
pathway by DEX leads to cardiac hypertrophy since
losartan ameliorated such changes. This is further
supported by increased expression of AT1 receptor
mRNAs by DEX (Fig. 3).
Extracellular matrix plays an important role in
regulating the function of cardiomyocytes besides
imparting the architectural support to the adjoining cells
[38]. Increased deposition of collagen in the ECM leads
to fibrosis which cause contractile abnormality and
reduced heart beat [14]. In the present study also, DEX
causes increased collagen deposition which might be
responsible for reduced heart beat (Table 2). Fibrosis is
also directly responsible for reduced blood flow to the
heart due to increased distance between blood vessels
and the cardiomyocytes [15]. Therefore, oxygen
Fig. 8. Effect of mifepristone and
losartan on superoxide dismutase and
catalase in dexamethasone-treated rat
heart tissue. Activities of Cu,Zn-SOD (A)
and catalase (B) in LV tissues of rats
treated with vehicle (CON),
dexamethasone (DEX) or dexamethasone
along with mifepristone (DEX+MIF) or
losartan (DEX+LOS) for 15 days. The
results are mean ? SEM of 3 separate
animals (n=3) in each experimental
group.*P<0.01 control vs DEX.
Fig. 9. Schematic representation depicting possible mechanism
of glucocorticoid-induced cardiac dysfunction. Glucocorticoid
induces hypertension, cardiac hypertrophy, ECM remodeling
or fibrosis. Fibrosis may lead to low oxygen availability to the
cardiomyocytes resulting in hypoxic condition and oxidative
stress. In overall, glucocorticoid via GR may induce pathological
changes which possibly cause reduced cardiac output and LV
dysfunction where Ang II pathway is critically involved. Solid
line indicates direct involvement and dashed lines indicate
involvement of other intermediates.
consumption is reduced as shown in Fig. 4. This is further
supported by increased level of HIF 1? in DEX treated
rat heart (Fig. 5) which is a marker of hypoxia in cell
[39].
Sufficient oxygen supply to cardiac muscle is crucial
for survival of mammals due to its central role as an
electron acceptor in the mitochondrial respiratory chain
driving ATP synthesis. Mitochondria have been suggested
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9as the primary oxygen sensor and increased reactive
oxygen species (ROS) production originating from the
mitochondrial respiratory chain has been observed under
hypoxia [17, 40]. Since excessive generation of ROS is
known to cause increased lipid peroxidation in cell, in the
present study, increased level of lipid peroxidation probably
indicates a higher level of ROS in LV under hypoxic
condition (Fig. 6). As one of the markers of oxidative
stress, HSP-70 is increased in DEX-induced
hypertrophied heart which is further supported by
increased production of lactate in blood (Fig. 7). This is
consistent with reduced cellular respiration and a high
level of HIF-1? (Fig. 5). Moreover, in the present study,
SOD activity is increased (Fig. 8A) as a compensatory
response to protect the heart from ROS mediated damage.
However, a concomitant decrease in catalase activity (Fig.
8B) is indicative of an accumulation of H
2
O
2
, a potentially
toxic ROS capable of inflicting oxidative damage.
Amelioration of the deleterious effects of DEX by losartan
supports the idea that hypertension is associated with an
elevation of ROS and frequently also with an impairment
of endogenous antioxidant mechanisms [41]. A decrease
in cellular respiration and an increase in oxidative stress
may be directly responsible for poor heart function in many
pathophysiological situations.
In the present study also, the heart function is
drastically affected which is evident from reduced cardiac
output and remarkable alteration in diastolic parameter
(Table 2). The systolic parameter was also reduced
significantly by DEX, but not to the extent of diastolic
dysfunction, which might be due to the overall impairment
of the LV. Though the hemodynamic parameters in the
present study were measured in different settings of the
heart beats, in overall, these alterations reflect the actual
condition per se due to DEX treatment.
Angiotensin II may exert its numerous effects in
modulating cardiovascular physiology and pathology by
inducing signalling pathways in vascular smooth muscle
cells, endothelial cells, and cardiac fibroblasts, and by
affecting their interaction with the extracellular matrix.
These cascades of events, in addition to other
abnormalities, ultimately lead to cardiac dysfunction [24].
Similarly, it appears that GC (via induction of Ang II
pathway) evokes signaling events in the cardiac fibroblasts
and myocytes leading to cardiac fibrosis, decreased
cellular respiration, increased oxidative stress which could
be attributed to cardiac malfunction (Fig. 9). However,
the present study does not conclusively demonstrate
whether all these events are in direct consequences of
glucocorticoid-induced fibrosis. Some of these events
might be due to secondary effects of glucocorticoid. On
the other hand, nitric oxide system has also been implicated
in glucocorticoid induced hypertension [42, 43]. Therefore,
the involvement of pathways other than AT 1 receptor in
glucocorticoid-mediated hypertension and oxidative stress
may also be possible [42-44]. In overall, it is likely that
excessive use of this anti-inflammatory drug could evoke
Ang II pathway leading to cardiotoxicity in the long run.
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